Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53 - PubMed (original) (raw)

Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53

N C Reich et al. Mol Cell Biol. 1983 Dec.

Abstract

The steady-state levels of p53 protein and p53 mRNA in transformed and nontransformed cells were examined to elucidate the mechanisms controlling expression of p53. mRNA levels were determined by Northern blot hybridization analysis, employing a p53-specific cDNA clone (M. Oren and A.J. Levine, Proc. Natl. Acad. Sci. U.S.A. 80:56-59, 1983), and protein levels were determined by the Western blotting technique. Analysis of p53 mRNA revealed a single polyadenylated mRNA species migrating at ca. 18S. Levels of p53 mRNA in simian virus 40-transformed cell line (SVT2) and in an homologous nontransformed cell line (3T3) were equivalent, although the steady-state levels of p53 protein were 25- to 100-fold higher in the SVT2 cells than in the 3T3 cells. A study with a non-virus-transformed cell system revealed a different result. Embryonal carcinoma cells (F9) were found to have nearly 20-fold higher levels of p53 mRNA in comparison with differentiated benign progeny cells. In this system the difference in p53 mRNA levels corresponded to the difference in p53 protein levels. Pulse-chase experiments were performed to study the half-life of p53 protein in these four types of cells. The turnover of p53 protein occurred with biphasic kinetics. In addition, it was found that protein synthesis inhibitors placed in the medium during the chase period prevented the turnover of p53 protein in transformed cells, but not in nontransformed (3T3) cells. These results provide evidence that the regulation of p53 expression in cells can occur at the level of p53 mRNA abundancy or p53 protein stability depending upon the experimental system under study, and that a regulated degradation process controls the turnover of p53 protein.

PubMed Disclaimer

Similar articles

• Regulation of the cellular p53 tumor antigen in teratocarcinoma cells and their differentiated progeny.
  Oren M, Reich NC, Levine AJ. Oren M, et al. Mol Cell Biol. 1982 Apr;2(4):443-9. doi: 10.1128/mcb.2.4.443-449.1982. Mol Cell Biol. 1982. PMID: 6287239 Free PMC article.
• Molecular cloning of a cDNA specific for the murine p53 cellular tumor antigen.
  Oren M, Levine AJ. Oren M, et al. Proc Natl Acad Sci U S A. 1983 Jan;80(1):56-9. doi: 10.1073/pnas.80.1.56. Proc Natl Acad Sci U S A. 1983. PMID: 6296874 Free PMC article.
• UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
  Maltzman W, Czyzyk L. Maltzman W, et al. Mol Cell Biol. 1984 Sep;4(9):1689-94. doi: 10.1128/mcb.4.9.1689-1694.1984. Mol Cell Biol. 1984. PMID: 6092932 Free PMC article.
• [Isolation and characteristics of clones complementary to mRNA of the murine cellular tumor antigen p53].
  Chumakov PM, Iotsova VS, Ninkina NN, Bukhman VL, Georgiev GP. Chumakov PM, et al. Genetika. 1988 Apr;24(4):602-12. Genetika. 1988. PMID: 2840339 Russian.
• The regulation of a cellular protein, p53, in normal and transformed cells.
  Levine AJ, Reich N, Thomas R. Levine AJ, et al. Prog Clin Biol Res. 1983;119:159-69. Prog Clin Biol Res. 1983. PMID: 6306685 Review. No abstract available.

Cited by

• DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice.
  Chai D, Wang X, Neeli P, Zhou S, Yu X, Sabapathy K, Li Y. Chai D, et al. Genes Dis. 2023 Jun 23;11(4):100994. doi: 10.1016/j.gendis.2023.04.027. eCollection 2024 Jul. Genes Dis. 2023. PMID: 38560504 Free PMC article.
• Identification of a small-molecule RPL11 mimetic that inhibits tumor growth by targeting MDM2-p53 pathway.
  Wang B, Gao J, Zhao Z, Zhong X, Cui H, Hou H, Zhang Y, Zheng J, Di J, Liu Y. Wang B, et al. Mol Med. 2022 Sep 7;28(1):109. doi: 10.1186/s10020-022-00537-x. Mol Med. 2022. PMID: 36071402 Free PMC article.
• Pattern of nucleotide variants of TP53 and their correlation with the expression of p53 and its downstream proteins in a Sri Lankan cohort of breast and colorectal cancer patients.
  Manoharan V, Karunanayake EH, Tennekoon KH, De Silva S, Imthikab AIA, De Silva K, Angunawela P, Vishwakula S, Lunec J. Manoharan V, et al. BMC Cancer. 2020 Jan 30;20(1):72. doi: 10.1186/s12885-020-6573-5. BMC Cancer. 2020. PMID: 32000721 Free PMC article.
• Nucleotide variants and protein expression of TP53 in a Sri Lankan cohort of patients with head and neck cancer.
  Manoharan V, Karunanayake EH, Tennekoon KH, De Silva S, De Silva K, Angunawela P, Lunec J. Manoharan V, et al. Mol Med Rep. 2019 Apr;19(4):2781-2791. doi: 10.3892/mmr.2019.9948. Epub 2019 Feb 11. Mol Med Rep. 2019. PMID: 30816478 Free PMC article.
• In-Tether Chiral Center Induced Helical Peptide Modulators Target p53-MDM2/MDMX and Inhibit Tumor Growth in Stem-Like Cancer Cell.
  Hu K, Yin F, Yu M, Sun C, Li J, Liang Y, Li W, Xie M, Lao Y, Liang W, Li ZG. Hu K, et al. Theranostics. 2017 Oct 13;7(18):4566-4576. doi: 10.7150/thno.19840. eCollection 2017. Theranostics. 2017. PMID: 29158845 Free PMC article.

References

1. 1. J Cell Physiol. 1968 Oct;72(2):141-8 - PubMed
2. 1. Biochemistry. 1977 Oct 18;16(21):4743-51 - PubMed
3. 1. Nature. 1979 Mar 15;278(5701):261-3 - PubMed
4. 1. Proc Natl Acad Sci U S A. 1979 May;76(5):2420-4 - PubMed
5. 1. Cell. 1979 May;17(1):43-52 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Taylor & Francis

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal